To compare hemoglobin degradation and bilirubin production before and during phototherapy in preterm infants.
Phototherapy has become a standard of care in the practice of neonatal/perinatal medicine for treating hyperbilirubinemia. [1] [2] [3] [4] [5] [6] [7] [8] [9] Some experts recommend prophylactic phototherapy in tiny preterm infants. 10 -12 However, it is unclear at what serum bilirubin level in tiny neonates central nervous system toxicity and/or damage may occur and at what level of serum bilirubin phototherapy treatment should be initiated and later discontinued.
Phototherapy in tiny preterm infants has many hazards, 13 including, but not limited to, increased insensible water loss 14, 15 and electrolyte imbalance. 16 This study examined the effect of phototherapy on hemoglobin degradation and bilirubin production in preterm infants.
METHODS
The study subjects were 24 preterm neonates in the neonatal intensive care unit of St. Vincent Medical Center in Toledo, Ohio. Included in the study were stable preterm infants who were judged by the attending neonatologist to require phototherapy. Excluded were infants with hemolytic diseases, sepsis, recent blood transfusions, and mechanical ventilation. The study was approved by the Institutional Review Board, and informed parental consent was obtained before enrolling each neonate in the study.
The end-tidal carbon monoxide (ETCO c ) was measured using an automated analyzer (Baby's Breath; Natus Medical, Inc., San Carlos, CA). A 5-Fr catheter was placed 1 cm into the anterior nares of the infant, and the exhaled breath samples were collected from the quietly resting infant in triplicate and simultaneously analyzed. Three consecutive ETCO c measurements were performed immediately before starting phototherapy and repeated at 3 to 30 hours after starting phototherapy. The average of within-subject coefficient of variation for ETCO c before phototherapy was 0.14; during phototherapy it was 0.13.
All laboratory tests, including hemoglobin, hematocrit, reticulocyte counts, Coomb's test, serum bilirubin, and blood group were determined by standard laboratory methods at St. Vincent Medical Center Laboratory.
Phototherapy light composed of four white and four blue fluorescent bulbs placed about 45 cm over the infant. Light intensity used was 5 to 10 W/cm 2 per nanometer. The correlation between heme degradation and bilirubin production; carboxyhemoglobin, respiratory excretion of carbon monoxide, and end-tidal CO, was previously established and published. [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] Original Article
An infant peak ETCO c of the triplicate measurements before phototherapy was used to represent the uncontaminated first ETCO c . The peak ETCO c during phototherapy represents the second ETCO c .
Statistical analysis was performed with a paired t test to compare ETCO c before and during phototherapy.
Data were analyzed using a software package (PC-Statistic, version 2.5; Franklin, Needle and Associates, Inc., Wilsonville, OR) and are expressed as mean Ϯ SD.
RESULTS
Twenty-four preterm infants participated in this study; 10 were female and 14 male.
All infants were treated with phototherapy for hyperbilirubinemia. None had pathologic jaundice, and none were treated prophylactically with phototherapy.
The mean Ϯ SD birth weight of these 24 preterm neonates was 1975 Ϯ 613 gm, gestational age was 32.7 Ϯ 2.3 weeks, hematocrit was 47.5 Ϯ 6.2 volume %, and peak bilirubin was 13.1 Ϯ 3.2 mg/dl ( Table 1 ). The first ETCO c measurements were done at 59.6 Ϯ 22.2 hours of age immediately before starting phototherapy. The second ETCO c measurements were done at 13.7 Ϯ 7.9 hours after starting phototherapy. The mean Ϯ SD of the second measurement, 2.6 Ϯ 0.6 ppm, was significantly higher than that of the first measurement, which was 2.1 Ϯ 0.6 ppm ( p Ͻ 0.05) ( Table 2) .
DISCUSSION
Current data regarding hemoglobin degradation and bilirubin production in normal newborn infants indicate that both decrease with increasing postnatal age. 19, 20, 28, 31 These data were generated from measuring carbon monoxide production.
The data from this study indicate that phototherapy increases hemoglobin degradation and subsequently increases bilirubin production in preterm infants.
This is important as it may implicate phototherapy as an additional factor in the mechanism of anemia of prematurity. It may also account for the increased length of time infants treated with prophylactic phototherapy spend under the light, compared with similar infants treated with phototherapy for hyperbilirubinemia. 32 Brown et al. 33 showed that phototherapy is efficacious in the treatment of hyperbilirubinemia in the newborn. The phototherapy- treated group had lower serum bilirubin levels and lower exchange transfusion rate than the control group. However, it is interesting to note in the same study that, when phototherapy was used to prevent hyperbilirubinemia in infants with birth weight Ͻ 2000 gm, the earliest result of the phototherapy was not a decrease in serum bilirubin, but rather a slower rate of increase. In contrast, infants with a birth weight of 2000 gm or more, who were treated with phototherapy for controlling bilirubin level, experienced an initial response that was a decrease in serum bilirubin level. Phototherapy is a valuable therapeutic tool in the neonatologist's armamentarium to treat hyperbilirubinemia, and it has been used since it was first described by Cremer et al. 34 in 1958. However, phototherapy is not risk-free, and there are few studies that address its complications and side effects. Adverse effects include increased insensible water loss, 14, 15 electrolyte imbalance, 16 retinal and ocular injury, 35, 36 increased gastrointestinal motility, 37, 38 loss of nutrients and vitamins, 16, 37, 39 hypocalcemia, 40 changes in gonadotropin levels, 41 disturbance of blood flow, 42 DNA breaks, 43 cellular damage, 44 accidental hypoxia, 45 parental separation and anxiety, and parental infant behavior changes. 46 -48 Lipsitz et al. 49 studied neonatal and infant mortality in relation to phototherapy and found that the number of infants with intracranial hemorrhage and/or pulmonary hemorrhage was higher in the phototherapy group than in the control group, although the difference was not statistically significant.
Red blood cells are adversely affected by phototherapy. Cukier et al. 50 discovered that phototherapy increased erythrocyte's osmotic fragility in chronically jaundiced rats. Ostrea et al. 51 proved that phototherapy causes damage to red blood cells in vitro. Jahrig et al. 52 showed that phototherapy causes photodynamic injury to the erythrocytes. Also, because phototherapy can cause cellular injury, a small portion of the elevated ETCO could be a result of injury to other tissues containing hemeproteins, like myoglobin, catalase, peroxidase, cytochromes, and NO synthase.
Curtis-Cohen et al. 32 showed, in a randomized trial of prophylactic phototherapy in very low birth weight infants, that infants in the prophylactic phototherapy treatment group were under phototherapy for a significantly longer time than the routine phototherapy group in which phototherapy was started at a serum bilirubin level of 5 mg/dl. There was no significant difference between the groups in the rate of rise in bilirubin, peak serum bilirubins, and the age at which it peaked. They concluded that prophylactic phototherapy has no beneficial effect in infants weighing Ͻ 1250 gm.
Several studies showed that phototherapy efficiency depends on serum bilirubin concentration. 53, 54 This could be explained if one considers that phototherapy-induced bilirubin production at lower serum bilirubin levels may be as high as phototherapy bilirubin elimination.
The data from this study demonstrate that phototherapy in small infants leads to more hemoglobin degradation and subsequently more bilirubin production. The use of phototherapy as a "prophylactic" measure or at low bilirubin levels to prevent hyperbilirubinemia may complicate the care of small preterm infants and offers no advantage over using phototherapy as a treatment at higher bilirubin levels. Additionally, when using phototherapy for treatment only at higher serum bilirubin levels, there will be a number of infants who will never need phototherapy and, therefore, will not be exposed to the phototherapy risks and complications associated with it.
In conclusion, phototherapy causes increases in both hemoglobin degradation and bilirubin production in preterm infants. Clinicians should take this into consideration when making a decision regarding when to initiate and discontinue phototherapy.
